Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CART19 for Adolescents and Young Adults With Systemic Lupus Erythematosus (SLE)
NCT06839976Phase 2Recruiting
- Sponsor
- Children's Hospital of Philadelphia
- Start
- May 2025
- Primary completion
- Feb 2030
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ARI-0001 in systemic lupus erythematosus (SLE), sponsored by Children's Hospital of Philadelphia. Primary endpoint: Dose Limiting Toxicities at 24 months. Started May 2025; status: recruiting.
02
Drugs
ARI-0001
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT06839976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06839976.